Investigational drug · Phase 2
EVM14
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Selected Types of Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "EVM14"
First trial start
2025
Nov 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EVM14", any sponsor or status.
Conditions studied
As listed on its trial records.
- Selected Types of Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "EVM14" as an intervention, largest first.
Everest Medicines (Beijing) Co., Ltd.Industry
NCT07095868 · 94 participants (planned) · Start Nov 17, 2025 · Primary completion Nov 2029
Drug: EVM14 · For: Selected Types of Solid Tumor
Sites: New York, New York; Houston, Texas; Fairfax, Virginia · 7 sites in all
- Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC PatientsNot yet recruiting
Everest Medicines (Beijing) Co., Ltd.Industry
NCT07614646 · 13 participants (planned) · Start Nov 2026 · Primary completion Jul 2028
Drug: EVM14; Ivonescimab · For: Squamous Non-Small Cell Lung Cancer sqNSCLC
Newest research
PubMed records naming it or its code names, newest first.
- Potential Probiotic Lactic Acid Bacteria with Anti-Penicillium expansum Activity from Different Species of Tunisian Edible Snails.
Rabaoui G, Sánchez-Juanes F, Tebini M, et al. · Probiotics Antimicrob Proteins 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.